Your browser is no longer supported. Please, upgrade your browser.
ALT Altimmune, Inc. monthly Stock Chart
ALT [NASD]
Altimmune, Inc.
Index- P/E- EPS (ttm)-2.00 Insider Own1.40% Shs Outstand33.06M Perf Week31.22%
Market Cap387.94M Forward P/E- EPS next Y-0.09 Insider Trans332.26% Shs Float30.91M Perf Month7.00%
Income-42.50M PEG- EPS next Q-0.78 Inst Own66.40% Short Float7.82% Perf Quarter-27.50%
Sales6.40M P/S60.61 EPS this Y89.50% Inst Trans69.20% Short Ratio1.47 Perf Half Y36.65%
Book/sh6.04 P/B2.02 EPS next Y96.60% ROA-38.30% Target Price- Perf Year571.98%
Cash/sh6.52 P/C1.88 EPS next 5Y- ROE-46.40% 52W Range1.60 - 35.10 Perf YTD547.09%
Dividend- P/FCF- EPS past 5Y50.20% ROI-47.00% 52W High-65.16% Beta1.62
Dividend %- Quick Ratio34.70 Sales past 5Y-10.70% Gross Margin- 52W Low664.37% ATR1.01
Employees25 Current Ratio34.70 Sales Q/Q383.30% Oper. Margin- RSI (14)59.62 Volatility12.45% 10.95%
OptionableYes Debt/Eq0.00 EPS Q/Q27.40% Profit Margin- Rel Volume2.28 Prev Close10.52
ShortableYes LT Debt/Eq0.00 EarningsNov 10 BMO Payout- Avg Volume1.64M Price12.23
Recom2.00 SMA2018.76% SMA504.15% SMA20012.10% Volume3,736,763 Change16.25%
Nov-12-20Reiterated B. Riley Securities Buy $31 → $28
Sep-25-20Initiated B. Riley FBR Buy $31
Aug-14-20Initiated Evercore ISI Outperform
Jul-31-20Initiated Piper Sandler Overweight $80
Jul-28-20Initiated JMP Securities Mkt Outperform $50
Feb-24-20Resumed ROTH Capital Buy $13
Jul-19-19Initiated ROTH Capital Buy $8.30
Oct-09-17Initiated Piper Jaffray Overweight $6
Nov-25-20 07:00AM  
Nov-16-20 07:00AM  
Nov-13-20 05:23AM  
Nov-10-20 01:00AM  
Nov-09-20 04:05PM  
Nov-03-20 08:00AM  
Oct-30-20 02:40PM  
Oct-26-20 06:22AM  
Oct-15-20 07:00AM  
Oct-13-20 04:56AM  
Oct-12-20 07:01AM  
Sep-30-20 07:00AM  
Sep-28-20 04:01PM  
Sep-01-20 07:00AM  
Aug-27-20 08:17AM  
Aug-26-20 07:00AM  
Aug-25-20 07:00AM  
Aug-11-20 04:05PM  
Aug-07-20 07:00AM  
Aug-05-20 07:00AM  
Jul-22-20 07:30AM  
Jul-16-20 04:01PM  
Jul-13-20 09:40PM  
04:01PM  
07:00AM  
Jul-09-20 11:30AM  
07:00AM  
Jul-08-20 08:04AM  
Jul-02-20 07:30PM  
Jun-30-20 07:00AM  
Jun-29-20 07:00AM  
Jun-22-20 07:00AM  
Jun-21-20 07:00AM  
Jun-17-20 08:45AM  
Jun-10-20 09:15AM  
Jun-09-20 09:15AM  
Jun-01-20 07:00AM  
May-28-20 11:34AM  
May-15-20 08:58AM  
May-13-20 05:18PM  
05:18PM  
09:15AM  
May-12-20 07:00AM  
May-09-20 08:11AM  
May-08-20 07:00AM  
May-06-20 02:50PM  
Apr-20-20 09:01AM  
Apr-13-20 08:58AM  
Apr-08-20 09:15AM  
Apr-02-20 02:51PM  
Mar-30-20 07:00AM  
Mar-27-20 07:15AM  
06:30AM  
Mar-25-20 04:30PM  
Feb-28-20 07:00AM  
Feb-19-20 04:30PM  
Feb-04-20 07:00AM  
Jan-31-20 04:58PM  
Jan-23-20 07:00AM  
Jan-07-20 08:43AM  
Dec-23-19 03:59PM  
Nov-21-19 08:00AM  
Nov-13-19 04:15PM  
Nov-11-19 05:43AM  
Nov-06-19 07:00AM  
Nov-01-19 02:41PM  
Oct-10-19 07:00AM  
Sep-09-19 07:00AM  
Aug-21-19 07:00AM  
Aug-13-19 04:15PM  
Aug-07-19 11:27AM  
Aug-05-19 07:00AM  
Jul-15-19 07:00AM  
Jul-12-19 02:55PM  
Jul-09-19 04:45PM  
01:39PM  
08:48AM  
07:15AM  
07:00AM  
Jun-12-19 08:00AM  
Jun-10-19 08:00AM  
Jun-05-19 08:00AM  
May-14-19 04:15PM  
May-08-19 08:00AM  
Apr-11-19 09:27AM  
Apr-02-19 06:30AM  
Apr-01-19 04:20PM  
Mar-21-19 04:15PM  
Mar-19-19 12:21PM  
08:12AM  
07:00AM  
Mar-14-19 09:00AM  
Mar-12-19 01:34PM  
Mar-08-19 09:29AM  
Jan-29-19 08:00AM  
Dec-14-18 07:00AM  
Dec-13-18 07:01AM  
Nov-30-18 06:06PM  
Nov-27-18 09:00AM  
Nov-23-18 07:00AM  
Altimmune, Inc., a clinical stage biopharmaceutical company, focused developing treatments for liver disease, immune modulating therapies, and vaccines. The company develops HepTcell, an immunotherapeutic product candidate that has completed Phase I clinical trial for patients chronically infected with the hepatitis B virus; NasoShield, an anthrax vaccine to provide for protection after a single intranasal administration; NasoVAX, a recombinant intranasal vaccine product candidate; and AdCOVID, a single-dose intranasal vaccine to protect against COVID-19 Its preclinical stage products include ALT-801, a novel peptide-based dual GLP-1/Glucagon receptor agonist for the treatment of non-alcoholic steatohepatitis; and ALT-702, an investigational tumor immunostimulant for treating cancer. The company also develops veterinary product candidates. It has a collaboration with the University of Alabama at Birmingham for the development of AdCOVID. Altimmune, Inc. is headquartered in Gaithersburg, Maryland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Drutz DavidDirectorNov 13Option Exercise2.406014417,603Nov 17 07:00 PM
Harris Matthew ScottDirectorNov 12Sale10.024,01540,2304,069Nov 13 06:00 PM
Pisano WayneDirectorNov 12Sale9.9010,352102,4858,498Nov 13 06:00 PM
Schafer KlausDirectorNov 12Sale9.9110,150100,5876,900Nov 13 06:00 PM
Hodges PhilipDirectorSep 24Option Exercise0.0016,850036,306Oct 16 07:00 PM
Pisano WayneDirectorSep 24Option Exercise0.0016,850018,850Oct 16 07:00 PM
GILL JOHNDirectorSep 24Option Exercise0.0016,850019,624Oct 16 07:00 PM
SAYARE MITCHELDirectorSep 24Option Exercise0.0025,275026,363Oct 16 07:00 PM
Schafer KlausDirectorSep 24Option Exercise0.0016,850017,050Oct 16 07:00 PM
Drutz DavidDirectorSep 24Option Exercise0.0016,850017,543Oct 16 07:00 PM
Venrock Healthcare Capital Par10% OwnerJun 15Buy7.541,500,00011,310,0004,500,000Jun 15 03:23 PM
Venrock Healthcare Capital Par10% OwnerMay 28Buy8.72201,4741,757,0903,000,000May 28 06:34 PM
Venrock Healthcare Capital Par10% OwnerMay 27Buy7.71402,1623,098,7612,798,526May 28 06:34 PM
Venrock Healthcare Capital Par10% OwnerMay 26Buy9.34700,0006,539,6422,396,364May 28 06:34 PM
VELOCITY PHARMACEUTICAL HOLDIN10% OwnerMay 15Sale4.6530,622142,3921,687,250May 18 04:45 PM
VELOCITY PHARMACEUTICAL HOLDIN10% OwnerMay 14Sale4.81169,378814,7081,717,872May 18 04:45 PM